Irina Kontsevaya - Concepedia

Author

Irina Kontsevaya

Queen Mary University of London ORCID

Also Known As

Abigail Seeger, Christoph Lange, I. Kontsevaya, I. S. Kontsevaya, I.S. Kontsevaya, Irina Kontsevaya, Kontsevaya, Irina

Publications

2.4K

Citations

H-Index

Concepts

All Affiliations

Queen Mary University of London Samara Medical Institute Reaviz Imperial College London Research Center Borstel - Leibniz Lung Center German Center for Infection Research

About

Irina Kontsevaya is an author at Queen Mary University of London specializing in medicine, tuberculosis, and tuberculosis diagnostics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	1.2K
2	Health Sciences	3	3	73
3	Public Health	2	2	46
4	Epidemiology	2	2	510
5	Biostatistics	1	1	30

Irina Kontsevaya

Publications

1.6K

Citations

H-Index

Page 1

	Year	Citations
Evolutionary history and global spread of the Mycobacterium tuberculosis Beijing lineage Matthias Merker, Camille Blin, Stefano Mona, Nature Genetics Global SpreadPulmonary TuberculosisPhylogeneticsEvolutionary HistoryTuberculosis Prevention	2015	554
Evolution and transmission of drug-resistant tuberculosis in a Russian population Nicola Casali, Vladyslav Nikolayevskyy, Yanina Balabanova, Nature Genetics Pulmonary TuberculosisRussian PopulationTuberculosis PreventionTuberculosisTuberculosis Diagnostics	2014	494
Microevolution of extensively drug-resistant tuberculosis in Russia Nicola Casali, Vladyslav Nikolayevskyy, Yanina Balabanova, Genome Research	2012	184
Proposal of a Consensus Set of Hypervariable Mycobacterial Interspersed Repetitive-Unit–Variable-Number Tandem-Repeat Loci for Subtyping of Mycobacterium tuberculosis Beijing Isolates Caroline Allix‐Béguec, Céline Wahl, M. Hanekom, Journal of Clinical Microbiology	2013	84
Prediction of anti-tuberculosis treatment duration based on a 22-gene transcriptomic model Jan Heyckendorf, Sebastian Marwitz, Maja Reimann, European Respiratory Journal	2021	56
Detection of Resistance to Second-Line Antituberculosis Drugs by Use of the Genotype MTBDR <i>sl</i> Assay: a Multicenter Evaluation and Feasibility Study Olga Ignatyeva, Irina Kontsevaya, Alexander Kovalyov, Journal of Clinical Microbiology	2012	46
A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial Andreas H. Diacon, Clifton E. Barry, Alex Carlton, Nature Medicine	2024	38
Survival of Civilian and Prisoner Drug-Sensitive, Multi- and Extensive Drug- Resistant Tuberculosis Cohorts Prospectively Followed in Russia Yanina Balabanova, Vladyslav Nikolayevskyy, Olga Ignatyeva, PLoS ONE	2011	33
Performance of the GenoType® MTBDRPlus assay in routine settings: a multicenter study Edita Pimkina, Irina Kontsevaya, Vladyslav Nikolayevskyy, European Journal of Clinical Microbiology & Infectious Diseases Genetic AnalysisGenetic TestingGenotype® MtbdrplusMedicineGenetics	2011	30
Utility of propidium monoazide viability assay as a biomarker for a tuberculosis disease Vladyslav Nikolayevskyy, Paolo Miotto, Edita Pimkina, Tuberculosis Pulmonary TuberculosisHealth SciencesPropidium Monoazide ViabilityMedicineTuberculosis Disease	2014	27

Page 1